Malcolm Robinson

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia
    M Robinson
    University of Oklahoma College of Medicine, Oklahoma Foundation for Digestive Research, Oklahoma City, USA
    Aliment Pharmacol Ther 13:5-10. 1999
  2. ncbi request reprint Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases
    M Robinson
    University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA
    Int J Clin Pract 59:709-15. 2005
  3. ncbi request reprint Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders
    M Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma, Oklahoma City, OK 74104, USA
    Aliment Pharmacol Ther 20:30-7. 2004
  4. ncbi request reprint Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications
    M Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma, Oklahoma City, OK 73104, USA
    Aliment Pharmacol Ther 20:1-10. 2004
  5. ncbi request reprint Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know
    Malcolm Robinson
    Department of Medicine, Oklahoma Foundation for Digestive Research, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA
    Drugs 63:2739-54. 2003
  6. ncbi request reprint Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis
    M Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104 5022, USA
    Aliment Pharmacol Ther 16:445-54. 2002
  7. ncbi request reprint Dyspepsia: challenges in diagnosis and selection of treatment
    M Robinson
    University of Oklahoma College of Medicine, Oklahoma Foundation for Digestive Research, Oklahoma City 73104 5022, USA
    Clin Ther 23:1130-44; discussion 1129. 2001
  8. ncbi request reprint New-generation proton pump inhibitors: overcoming the limitations of early-generation agents
    M Robinson
    Department of Medicine, University of Oklahoma, Oklahoma City, USA
    Eur J Gastroenterol Hepatol 13:S43-7. 2001
  9. ncbi request reprint Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole
    Malcolm Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma, Health Sciences Center, Oklahoma City, USA
    Dig Dis Sci 47:265-73. 2002
  10. pmc Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors
    Lauren B Gerson
    Stanford University School of Medicine, Stanford, CA, USA
    BMC Gastroenterol 8:15. 2008

Detail Information

Publications11

  1. ncbi request reprint Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia
    M Robinson
    University of Oklahoma College of Medicine, Oklahoma Foundation for Digestive Research, Oklahoma City, USA
    Aliment Pharmacol Ther 13:5-10. 1999
    ..Furthermore, neither animal nor human data obtained with rabeprazole suggest a significant risk for neoplastic changes secondary to hypergastrinaemia...
  2. ncbi request reprint Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases
    M Robinson
    University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA
    Int J Clin Pract 59:709-15. 2005
    ..New data, in addition, highlight differences in PPI metabolism that may both affect efficacy and predispose patients to drug-drug interactions. PPI selection should involve the awareness of these issues...
  3. ncbi request reprint Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders
    M Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma, Oklahoma City, OK 74104, USA
    Aliment Pharmacol Ther 20:30-7. 2004
    ....
  4. ncbi request reprint Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications
    M Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma, Oklahoma City, OK 73104, USA
    Aliment Pharmacol Ther 20:1-10. 2004
    ..A brief overview presents the pharmacodynamics and pharmacokinetics of the proton pump inhibitors with particular attention paid to rabeprazole, one of the newer drugs in its class...
  5. ncbi request reprint Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know
    Malcolm Robinson
    Department of Medicine, Oklahoma Foundation for Digestive Research, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA
    Drugs 63:2739-54. 2003
    ..g. increased digoxin absorption or inability to absorb ketoconazole)...
  6. ncbi request reprint Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis
    M Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104 5022, USA
    Aliment Pharmacol Ther 16:445-54. 2002
    ..In numerous clinical trials, proton pump inhibitors have demonstrated potent acid suppression and healing of erosive oesophagitis, as well as successful symptom relief for the entire spectrum of gastro-oesophageal reflux disease...
  7. ncbi request reprint Dyspepsia: challenges in diagnosis and selection of treatment
    M Robinson
    University of Oklahoma College of Medicine, Oklahoma Foundation for Digestive Research, Oklahoma City 73104 5022, USA
    Clin Ther 23:1130-44; discussion 1129. 2001
    ..Despite considerable study, the pathophysiology of dyspepsia remains obscure. This and other factors have impeded development of precise and effective treatment strategies...
  8. ncbi request reprint New-generation proton pump inhibitors: overcoming the limitations of early-generation agents
    M Robinson
    Department of Medicine, University of Oklahoma, Oklahoma City, USA
    Eur J Gastroenterol Hepatol 13:S43-7. 2001
    ..Unlike esomeprazole, the use of rabeprazole is not complicated by clinically significant drug-drug interactions of the type that have been reported for omeprazole and the wide range of medications metabolized by CYP 2C19...
  9. ncbi request reprint Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole
    Malcolm Robinson
    Oklahoma Foundation for Digestive Research, University of Oklahoma, Health Sciences Center, Oklahoma City, USA
    Dig Dis Sci 47:265-73. 2002
    ....
  10. pmc Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors
    Lauren B Gerson
    Stanford University School of Medicine, Stanford, CA, USA
    BMC Gastroenterol 8:15. 2008
    ..A Stanford University study reported that in asymptomatic GERD patients who were being treated with a proton pump inhibitor (PPI), 50% had pathologic esophageal acid exposure...
  11. ncbi request reprint Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration
    Jerry D Gardner
    Science for Organizations, Inc, Chatham, New Jersey 07928, USA
    J Appl Physiol 92:427-34. 2002
    ..72; P = 0.0001). Thus intragastric autotitration is a convenient, reproducible method for measuring gastric acid secretion after ingestion of a solid meal and offers several advantages over manual intragastric titration...